RS-2023-00258675

Development of mRNA-encoded NK cell engager for the treatment of relapsed/refractory B cell lymphoma

De novo Biotherapeutics

De novo Biotherapeutics

ONCOLOGY | **Hit**

Product Type	mRNA-encoded, NK cell engaging bispecific antibody
Indication	B cell lymphoma
Target	CD20/NK cell activating receptor
MoA(Mechanism of Action)	1. LNP-encapsulated mRNA encoding NK cell engager is administered intravenously. 2. They are delivered to the liver, and NK cell engagers are produced in the hepatocytes. 3. NK cell engagers redirect NK cells toward cancer cells, mediating antibody-dependent cellular cytotoxicity, ultimately resulting in the destruction of the cancer cells.
Competitiveness	1. Extended dosing interval, reduced dosing frequency 2. better safety profiles with lower incidence and severity of CRS and neurotoxicity compared to T cells
Development Stage	Hit
Route of Administration	Parental - Intravenous





kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund